The Tyrosine Kinase Inhibitor Bafetinib Inhibits PAR2-induced Activation of TRPV4 Channelsin Vitroand Painin Vivo

British Journal of Pharmacology - United States
doi 10.1111/bph.12750
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

Steroid-Sparing Therapy for Tyrosine Kinase Inhibitor–Induced Pneumonitis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor

Prescriber
Pharmacology
2018English

A Conditional Transmembrane Peptide Inhibits Cell Migration by Activation of the EphA2 Receptor Tyrosine Kinase

Biophysical Journal
Biophysics
2019English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Novel HER2 Selective Tyrosine Kinase Inhibitor, TAK-165, Inhibits Bladder, Kidney and Androgen-Independent Prostate Cancer in Vitro and in Vivo

International Journal of Urology
Urology
2006English

GSK2646264, a Spleen Tyrosine Kinase Inhibitor Attenuates the Release of Histamine in Ex Vivo Human Skin

British Journal of Pharmacology
Pharmacology
2019English

Targeting Tumour Microenvironment by Tyrosine Kinase Inhibitor

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2018English

TRPV4 Channel Inhibits TGF-β1-Induced Proliferation of Hepatic Stellate Cells

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy